Colorcon launches Opadry Enteric for use with hydro-alcoholic media
![](/46/pdcnewsitem/07/85/41/Colorcon%20launches%20Opadry%20Enteric%20for%20use%20with%20hydro-alcoholic%20media%20-%20CPhI%20Online%202019.jpeg)
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.
Colorcon has announced another innovative addition to their portfolio of delayed-release coatings for pharmaceutical applications. This latest development incorporates hydroxypropyl methylcellulose phthalate (hypromellose phthalate or HPMC-P) as the functional polymer in an advanced one-step film coating system offering enteric performance for hydro-alcoholic applications.
Opadry Enteric is a fully formulated one-step system providing simple preparation and ease-of-use for film coating; resulting in reduced inventory and QC testing compared to multi-component coating systems. This new system provides a further option to the company's existing Opadry delayed-release product line based on acrylic and PVAP polymers.
Dr Daniel To, Product Development Manager, explains: “As a fully formulated system Opadry Enteric, based on HPMC-P, brings not only convenience but also reduces potential errors of raw material handling and application during manufacturing. Our application data, generated during the product’s development, clearly demonstrates consistent and stable enteric performance for a number of APIs.”
Greater efficiency for solvent coating
Kelly Boyer, General Manager, Film Coatings at Colorcon notes: “Opadry Enteric is formulated for use with hydro-alcoholic media and can be color matched to meet the marketing and brand needs of pharmaceutical products. As a one-step hydro-alcoholic coating, preparation time is significantly reduced and, by using Colorcon’s expertise in color matching, batch-to-batch variability is eliminated.”
This new fully formulated delayed release coating, providing enteric protection represents Colorcon’s continued innovation and leadership in developing formulated film coating systems that bring enhanced functionality along with improved convenience for pharmaceutical formulators.
![Colorcon](https://www.cphi-online.com/ahdODTdzGmHUP55-comp248219.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance